Which periodic fever syndromes is canakinumab (Ilaris) indicated to treat in patients aged 2 years and older?

Canakinumab (Ilaris) treats patients aged ≥2 years with cryopyrin-associated periodic syndromes (Muckle-Wells, NOMID/CINCA, severe FCAS/FCU with symptoms beyond cold-induced urticarial rash), TNF receptor-associated periodic syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, or familial Mediterranean fever (with colchicine if appropriate).